It is currently trading at $6.25 just below the 50 day moving average which is $6.67 and which is slightly below the 200 day moving average of $6.42. The 50 day moving average was down $-0.42 or -6.34% and the 200 day average went down $-0.17 or -2.62%. Trading was heavy with 830 shares changing hands on Tuesday. Overall, volume was up 15.12% over the stocks normal daily volume.
Investors are feeling more bullish on shares of Cyclacel Pharmaceuticals, Inc. if you pay attention to the downtick in short interest. The stock recorded a fall in short interest of -19.80% between September 29, 2017 and October 13, 2017. Short shares decreased from 1,818 to 1,458 over that period. The short-interest ratio increased to 2.0 and the short interest percentage is 0.00% as of October 13.
These firms have modified their investment in CYCCP. As of quarter end Ubs Group Ag had disposed of 1,356 shares trimming its stake by 69.0%. The value of the investment in Cyclacel Pharmaceuticals, Inc. decreased from $12,000 to $4,000 decreasing 66.7% quarter over quarter. Tower Research Capital LLC (trc) trimmed its position by shedding 381 shares a decrease of 90.1% from 03/31/2017 to 06/30/2017. Tower Research Capital LLC (trc) currently owns 42 shares valued at $0. The total value of its holdings decreased 100.0%.
In the market the company is trading unchanged by % percent from yesterday’s close. Additionally Cyclacel Pharmaceuticals, Inc. recently declared a dividend for shareholders that was paid on Wednesday the 1st of November 2017. The dividend payment was $0.150 per share for the quarter which comes to $0.60 on an annualized basis. This dividend represents a yield of $8.78 which is the dividend as a percentage of the current share price. The ex-dividend date was Thursday the 12th of October 2017.
Cyclacel Pharmaceuticals, Inc., launched on January 5, 1996, operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Business’s family of anticancer drugs acts on the cell cycle..